DrugPatentWatch Database Preview
Details for Patent: 6,479,496
Which drugs does patent 6,479,496 protect, and when does it expire?
This patent has ninety-two patent family members in twenty-nine countries.
Summary for Patent: 6,479,496
Title: | Methods for treating angina with ranolazine |
Abstract: | A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 850 and 4000 ng base/mL. |
Inventor(s): | Wolff; Andrew A. (San Francisco, CA) |
Assignee: | CV Therapeutics, Inc. (Palo Alto, CA) |
Application Number: | 09/520,932 |
Patent Claim Types: see list of patent claims | Use; Dosage form; |
Drugs Protected by US Patent 6,479,496
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gilead | RANEXA | ranolazine | TABLET, EXTENDED RELEASE;ORAL | 021526-001 | Feb 12, 2007 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE | ➤ Sign Up | ||||
Gilead | RANEXA | ranolazine | TABLET, EXTENDED RELEASE;ORAL | 021526-002 | Jan 27, 2006 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE | ➤ Sign Up | ||||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Non-Orange Book US Patents Family Members for Patent 6,479,496
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
6,864,258 | Sustained release ranolazine formulations | ➤ Sign Up |
6,620,814 | Sustained release ranolazine formulations | ➤ Sign Up |
6,503,911 | Sustained release ranolazine formulations | ➤ Sign Up |
6,525,057 | Sustained release ranolazine formulations | ➤ Sign Up |
Patent No. | Title | Estimated Patent Expiration |
International Patents Family Members for US Patent 6,479,496
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Czech Republic | 20010879 | ➤ Sign Up | |||
Czech Republic | 301375 | ➤ Sign Up | |||
Czech Republic | 20022996 | ➤ Sign Up | |||
Germany | 69901570 | ➤ Sign Up | |||
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |